{"id":"NCT01125813","sponsor":"Octapharma","briefTitle":"Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A","officialTitle":"Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2010-05-18","resultsPosted":"2013-04-22","lastUpdate":"2017-09-11"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Severe Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"recombinant Factor VIII","otherNames":["human-cl rhFVIII"]}],"arms":[{"label":"human cl-rhFVIII","type":"EXPERIMENTAL"}],"summary":"This study will determine the efficacy of human-cl rhFVIII in previously treated patients with severe hemophilia A during prophylactic treatment, treatment of bleeding episodes and in surgical prophylaxis.","primaryOutcome":{"measure":"Efficacy Assessment After a Total of at Least 50 EDs Per Subject at the End of the Study at 6 Months","timeFrame":"At least 50 Exposure Days and at least 6 months","effectByArm":[{"arm":"Human Cl-rhFVIII","deltaMin":0.188,"sd":0.307}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":11,"countries":["Austria","Bulgaria","Germany","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":32},"commonTop":["Nasopharyngitis","Headache","Abdominal pain","Diarrhoea","Nausea"]}}